| Funding Opportunity ID: | 329109 |
| Opportunity Number: | PAR-20-301 |
| Opportunity Title: | Drug Development Collaboratory (UG3/UH3 Clinical Trial Required) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Health |
| Category Explanation: | |
| CFDA Number(s): | 93.350 |
| Eligible Applicants: | State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification) |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
| Agency Code: | HHS-NIH11 |
| Agency Name: | Department of Health and Human Services
National Institutes of Health |
| Posted Date: | Sep 18, 2020 |
| Close Date: | Jun 09, 2023 |
| Last Updated Date: | Sep 18, 2020 |
| Award Ceiling: | $0 |
| Award Floor: | $0 |
| Estimated Total Program Funding: | |
| Expected Number of Awards: | |
| Description: | The purpose of this Funding Opportunity Announcement (FOA) is to support intramural-extramural collaborations on late-stage translational science projects between NCATS Therapeutic Development Branch (TDB) and extramural researchers, for therapeutic development of small molecules, biologics, or gene therapies. The UG3 phase will provide support for late stage pre-clinical work and clinical trial planning that is conducted at applicant institutions. The goal of any collaboration with TDB is to enable an IND application by the end of the UG3 phase. If UG3 milestones are met and an IND is cleared, support may be provided for an early stage clinical trials in the UH3 phase that will be conducted at the applicant institutions. |
| Version: | 1 |
